

Product Datasheet

LY2562175

Catalog No. **BP-02141** · CAS **1103500-20-4** · Form **free base** · Physical state **other** · Color **White to light yellow** · Version **1.0**
· Revision **2026-09-03**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target FXR; Autophagy	Research area Metabolic Disease
---------------------------------	---

Molecular formula **C₂₈H₂₇Cl₂N₃O₄**

Molecular weight **540.4380**

STRUCTURE



DESCRIPTION

LY2562175 is a potent and selective farnesoid X receptor (FXR) agonist. LY2562175 promotes transcriptional activation of human FXR in a cell-based cotransfection assay with EC₅₀ of 193 nM.

BIOLOGICAL ACTIVITY

In Vitro

LY2562175 promotes transcriptional activation of human FXR in a cell-based co-transfection assay with an EC₅₀ of 193 nM. LY2562175 promotes recruitment of a peptide from the nuclear receptor interaction domain of the coactivator SRC-1 with a relative EC₅₀ of 121 nM and 93.5% efficacy as compare to GW4064.

In Vivo

LY2562175 causes a dose-dependent decrease in serum cholesterol and serum triglycerides. At a dose of 10 mg/kg, the decrease in cholesterol with LY2562175 is 80% below vehicle-treated animals, and the decrease in serum triglycerides is 76% from control group. The ED₅₀ for serum cholesterol is determined to be 2 and 3.4 mg/kg for serum triglycerides. Treatment of female ZDF rats with LY2562175 results in a dose dependent lowering of plasma triglycerides in the fasted and nonfasted states. When administered as a fixed dose combination with BRL49653, LY2562175 further lowers fasted and nonfasted plasma triglycerides. FPLC fractionation of the lipoproteins reveals that LY2562175 treatment results in a reduction in vLDL-C and a dramatic increase in HDL-c in this animal model.

SOLUBILITY

Soluble in DMF: 20 mg/ml

DMSO: 30 mg/ml

DMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml

REFERENCES

[1]. Genin MJ, et al. Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia. J Med Chem. 2015 Dec 24;58(24):9768-72.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.